Is CMPX or TYRA more profitable?

Compass Therapeutics' return on equity of -38.71% beat Tyra Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Compass Therapeutics N/A -38.71% -34.72% Tyra Biosciences N/A -46.39% -43.07%

Does the media favor CMPX or TYRA?

In the previous week, Tyra Biosciences had 11 more articles in the media than Compass Therapeutics. MarketBeat recorded 12 mentions for Tyra Biosciences and 1 mentions for Compass Therapeutics. Compass Therapeutics' average media sentiment score of 1.75 beat Tyra Biosciences' score of 0.53 indicating that Compass Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Tyra Biosciences 2 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer NVAX or CMPX?

In the previous week, Novavax had 10 more articles in the media than Compass Therapeutics. MarketBeat recorded 11 mentions for Novavax and 1 mentions for Compass Therapeutics. Compass Therapeutics' average media sentiment score of 1.75 beat Novavax's score of 0.66 indicating that Compass Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Compass Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger valuation & earnings, CMPX or AAPG?

Compass Therapeutics has higher earnings, but lower revenue than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Compass Therapeutics $850K 402.55 -$66.49M -$0.40 N/A Ascentage Pharma Group International $82.10M 17.13 -$177.71M N/A N/A

Is CMPX or AAPG more profitable?

Ascentage Pharma Group International's return on equity of 0.00% beat Compass Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Compass Therapeutics N/A -38.71% -34.72% Ascentage Pharma Group International N/A N/A N/A

Does the media favor CMPX or AAPG?

In the previous week, Compass Therapeutics and Compass Therapeutics both had 1 articles in the media. Compass Therapeutics' average media sentiment score of 1.75 beat Ascentage Pharma Group International's score of -0.71 indicating that Compass Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Ascentage Pharma Group International 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Is CMPX or FBRX more profitable?

Compass Therapeutics' return on equity of -38.71% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Compass Therapeutics N/A -38.71% -34.72% Forte Biosciences N/A -94.82% -77.68%

Compass Therapeutics (CMPX) Competitors

$1.90 +0.05 (+2.70%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.89 -0.01 (-0.58%)

As of 09/18/2026 07:56 PM Eastern

Compare

CMPX vs. TYRA, NVAX, ANAB, AAPG, and FBRX

Should you buy Compass Therapeutics stock or one of its competitors? Compass Therapeutics's main competitors and comparable companies include Tyra Biosciences (TYRA), Novavax (NVAX), AnaptysBio (ANAB), Ascentage Pharma Group International (AAPG), and Forte Biosciences (FBRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Compass Therapeutics compare to Tyra Biosciences?

Compass Therapeutics (NASDAQ:CMPX) and Tyra Biosciences (NASDAQ:TYRA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

Compass Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market.

Compass Therapeutics currently has a consensus target price of $11.77, indicating a potential upside of 519.43%. Tyra Biosciences has a consensus target price of $47.88, indicating a potential upside of 86.07%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Compass Therapeutics is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Compass Therapeutics' return on equity of -38.71% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-38.71%	-34.72%
Tyra Biosciences	N/A	-46.39%	-43.07%

68.4% of Compass Therapeutics shares are held by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are held by institutional investors. 18.7% of Compass Therapeutics shares are held by company insiders. Comparatively, 12.5% of Tyra Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Compass Therapeutics has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	$850K	402.55	-$66.49M	-$0.40	N/A
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.40	N/A

In the previous week, Tyra Biosciences had 11 more articles in the media than Compass Therapeutics. MarketBeat recorded 12 mentions for Tyra Biosciences and 1 mentions for Compass Therapeutics. Compass Therapeutics' average media sentiment score of 1.75 beat Tyra Biosciences' score of 0.53 indicating that Compass Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Tyra Biosciences	2 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Compass Therapeutics beats Tyra Biosciences on 13 of the 15 factors compared between the two stocks.

How does Compass Therapeutics compare to Novavax?

Novavax (NASDAQ:NVAX) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Novavax has higher revenue and earnings than Compass Therapeutics. Novavax is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.48	$440.30M	-$1.52	N/A
Compass Therapeutics	$850K	402.55	-$66.49M	-$0.40	N/A

Novavax has a beta of 2.45, indicating that its stock price is 145% more volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market.

53.0% of Novavax shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 1.6% of Novavax shares are held by insiders. Comparatively, 18.7% of Compass Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Novavax presently has a consensus target price of $14.00, indicating a potential upside of 38.48%. Compass Therapeutics has a consensus target price of $11.77, indicating a potential upside of 519.43%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Compass Therapeutics is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Novavax had 10 more articles in the media than Compass Therapeutics. MarketBeat recorded 11 mentions for Novavax and 1 mentions for Compass Therapeutics. Compass Therapeutics' average media sentiment score of 1.75 beat Novavax's score of 0.66 indicating that Compass Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Compass Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Compass Therapeutics has a net margin of 0.00% compared to Novavax's net margin of -59.87%. Novavax's return on equity of -14.82% beat Compass Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-59.87%	-14.82%	-13.35%
Compass Therapeutics	N/A	-38.71%	-34.72%

Summary

Compass Therapeutics beats Novavax on 11 of the 17 factors compared between the two stocks.

How does Compass Therapeutics compare to AnaptysBio?

Compass Therapeutics (NASDAQ:CMPX) and AnaptysBio (NASDAQ:ANAB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Compass Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.71, meaning that its stock price is 29% less volatile than the broader market.

Compass Therapeutics has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. AnaptysBio's return on equity of 0.00% beat Compass Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-38.71%	-34.72%
AnaptysBio	-11.53%	N/A	-7.75%

Compass Therapeutics presently has a consensus price target of $11.77, indicating a potential upside of 519.43%. AnaptysBio has a consensus price target of $79.85, indicating a potential upside of 44.65%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Compass Therapeutics is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
AnaptysBio	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

AnaptysBio has higher revenue and earnings than Compass Therapeutics. AnaptysBio is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	$850K	402.55	-$66.49M	-$0.40	N/A
AnaptysBio	$234.60M	6.97	-$13.23M	-$1.08	N/A

68.4% of Compass Therapeutics shares are owned by institutional investors. 18.7% of Compass Therapeutics shares are owned by insiders. Comparatively, 31.5% of AnaptysBio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Compass Therapeutics had 1 more articles in the media than AnaptysBio. MarketBeat recorded 1 mentions for Compass Therapeutics and 0 mentions for AnaptysBio. Compass Therapeutics' average media sentiment score of 1.75 beat AnaptysBio's score of 0.00 indicating that Compass Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Compass Therapeutics	Very Positive
AnaptysBio	Neutral

Summary

Compass Therapeutics beats AnaptysBio on 12 of the 17 factors compared between the two stocks.

How does Compass Therapeutics compare to Ascentage Pharma Group International?

Compass Therapeutics (NASDAQ:CMPX) and Ascentage Pharma Group International (NASDAQ:AAPG) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

Compass Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of 0.08, meaning that its stock price is 92% less volatile than the broader market.

Compass Therapeutics has higher earnings, but lower revenue than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	$850K	402.55	-$66.49M	-$0.40	N/A
Ascentage Pharma Group International	$82.10M	17.13	-$177.71M	N/A	N/A

68.4% of Compass Therapeutics shares are owned by institutional investors. 18.7% of Compass Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Compass Therapeutics and Compass Therapeutics both had 1 articles in the media. Compass Therapeutics' average media sentiment score of 1.75 beat Ascentage Pharma Group International's score of -0.71 indicating that Compass Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Ascentage Pharma Group International	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Compass Therapeutics currently has a consensus target price of $11.77, indicating a potential upside of 519.43%. Ascentage Pharma Group International has a consensus target price of $46.43, indicating a potential upside of 208.29%. Given Compass Therapeutics' higher possible upside, analysts clearly believe Compass Therapeutics is more favorable than Ascentage Pharma Group International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20

Ascentage Pharma Group International's return on equity of 0.00% beat Compass Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-38.71%	-34.72%
Ascentage Pharma Group International	N/A	N/A	N/A

Summary

Compass Therapeutics beats Ascentage Pharma Group International on 8 of the 13 factors compared between the two stocks.

How does Compass Therapeutics compare to Forte Biosciences?

Compass Therapeutics (NASDAQ:CMPX) and Forte Biosciences (NASDAQ:FBRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Compass Therapeutics has higher revenue and earnings than Forte Biosciences. Forte Biosciences is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	$850K	402.55	-$66.49M	-$0.40	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.65	N/A

Compass Therapeutics' return on equity of -38.71% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-38.71%	-34.72%
Forte Biosciences	N/A	-94.82%	-77.68%

68.4% of Compass Therapeutics shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 18.7% of Compass Therapeutics shares are owned by insiders. Comparatively, 4.4% of Forte Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Compass Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.62, indicating that its share price is 162% more volatile than the broader market.

Compass Therapeutics presently has a consensus price target of $11.77, indicating a potential upside of 519.43%. Forte Biosciences has a consensus price target of $71.67, indicating a potential downside of 6.91%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Compass Therapeutics is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Compass Therapeutics had 1 more articles in the media than Forte Biosciences. MarketBeat recorded 1 mentions for Compass Therapeutics and 0 mentions for Forte Biosciences. Compass Therapeutics' average media sentiment score of 1.75 beat Forte Biosciences' score of 0.00 indicating that Compass Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Compass Therapeutics	Very Positive
Forte Biosciences	Neutral

Summary

Compass Therapeutics beats Forte Biosciences on 13 of the 15 factors compared between the two stocks.

Get Compass Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CMPX vs. The Competition

Export

Metric	Compass Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$333.16M	$3.92B	$7.24B	$13.14B
Dividend Yield	N/A	3.65%	2.57%	12.30%
P/E Ratio	-4.75	14.30	275.79	25.40
Price / Sales	402.55	1,415.50	695.58	114.44
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	1.71	15.45	10.46	6.33
Net Income	-$66.49M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-5.00%	-1.21%	0.59%	1.12%
1 Month Performance	-23.39%	-4.42%	-2.01%	-2.67%
1 Year Performance	-43.95%	37.81%	18.09%	6.01%

Compass Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CMPX Compass Therapeutics	2.5 of 5 stars	$1.90 +2.7%	$11.77 +519.4%	-48.4%	$333.16M	$850K	N/A	39	Positive News High Trading Volume
TYRA Tyra Biosciences	3.4242 of 5 stars	$28.65 flat	$48.22 +68.3%	+101.2%	$1.71B	N/A	N/A	20	High Trading Volume
NVAX Novavax	2.5292 of 5 stars	$10.22 flat	$14.00 +37.0%	+18.5%	$1.69B	$1.12B	N/A	1,990
ANAB AnaptysBio	2.0692 of 5 stars	$56.80 flat	$79.85 +40.6%	+161.9%	$1.68B	$234.60M	N/A	100	Upcoming Earnings High Trading Volume
AAPG Ascentage Pharma Group International	2.8668 of 5 stars	$17.61 flat	$46.43 +163.6%	-61.7%	$1.65B	$82.10M	N/A	600

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CMPX) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compass Therapeutics (CMPX) Competitors

CMPX vs. TYRA, NVAX, ANAB, AAPG, and FBRX

How does Compass Therapeutics compare to Tyra Biosciences?

Summary

How does Compass Therapeutics compare to Novavax?

Summary

How does Compass Therapeutics compare to AnaptysBio?

Summary

How does Compass Therapeutics compare to Ascentage Pharma Group International?

Summary

How does Compass Therapeutics compare to Forte Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPX vs. The Competition

Compass Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compass Therapeutics (CMPX) Competitors

CMPX vs. TYRA, NVAX, ANAB, AAPG, and FBRX

How does Compass Therapeutics compare to Tyra Biosciences?

Which has more risk and volatility, CMPX or TYRA?

Do analysts rate CMPX or TYRA?

Is CMPX or TYRA more profitable?

Do insiders & institutionals believe in CMPX or TYRA?

Which has stronger earnings & valuation, CMPX or TYRA?

Does the media favor CMPX or TYRA?

Summary

How does Compass Therapeutics compare to Novavax?

Which has better earnings & valuation, NVAX or CMPX?

Which has more risk & volatility, NVAX or CMPX?

Do institutionals and insiders hold more shares of NVAX or CMPX?

Do analysts prefer NVAX or CMPX?

Does the media prefer NVAX or CMPX?

Is NVAX or CMPX more profitable?

Summary

How does Compass Therapeutics compare to AnaptysBio?

Which has more volatility and risk, CMPX or ANAB?

Is CMPX or ANAB more profitable?

Do analysts recommend CMPX or ANAB?

Which has preferable earnings & valuation, CMPX or ANAB?

Do insiders and institutionals believe in CMPX or ANAB?

Does the media favor CMPX or ANAB?

Summary

How does Compass Therapeutics compare to Ascentage Pharma Group International?

Which has more volatility & risk, CMPX or AAPG?

Which has stronger valuation & earnings, CMPX or AAPG?

Do insiders & institutionals believe in CMPX or AAPG?

Does the media favor CMPX or AAPG?

Do analysts recommend CMPX or AAPG?

Is CMPX or AAPG more profitable?

Summary

How does Compass Therapeutics compare to Forte Biosciences?

Which has stronger earnings & valuation, CMPX or FBRX?

Is CMPX or FBRX more profitable?

Do insiders and institutionals hold more shares of CMPX or FBRX?

Which has more risk & volatility, CMPX or FBRX?

Do analysts prefer CMPX or FBRX?

Does the media favor CMPX or FBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPX vs. The Competition

Compass Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools